Send me real-time posts from this site at my email
Zacks

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

Shares of AnaptysBio, Inc. ANAB were down 10.5% in after-hours trading on Monday after it announced top-line data from the phase II ACORN study, which evaluated its pipeline candidate, imsidolimab, for the treatment of moderate-to-severe acne.

The ACORN study failed to demonstrate efficacy over placebo on both primary and secondary endpoints. Owing to this, the company decided to discontinue the development of imsidolimab for the acne indication.

Shares of AnaptysBio have plunged 18.2% so far this year compared with the industry’s decline of 19.3%.


Image Source: Zacks Investment Research

AnaptysBio is also developing imsidolimab for addressing dermatological inflammatory diseases like generalized pustular psoriasis (“GPP”), and moderate-to-severe hidradenitis suppurativa, a chronic skin condition.

Enrollment is currently ongoing in the phase III GEMINI-1 GPP study on imsidolimab. The candidate has already demonstrated efficacy and safety in the phase II GALLOP study for treating GPP.

Meanwhile, the phase II HARP study is evaluating imsidolimab for the treatment of moderate-to-severe hidradenitis suppurativa. Top-line data from this study is expected in the second half of 2022.

Apart from imsidolimab, AnaptysBio is also developing two other wholly-owned programs — anti-PD-1 agonist, rosnilimab, and anti-BTLA modulator, ANB032.

The phase II AZURE study is evaluating rosnilimab for treating moderate-to-severe alopecia areata. Enrollment in the study is currently ongoing.

ANB032 is being developed as a potential treatment for inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company is advancing ANB032 in a healthy volunteer phase I study, with top-line data expected in the second quarter of 2022.

In the absence of a marketed product, successful development of the candidates remains in key focus for AnaptysBio.

Zacks Rank & Stocks to Consider

AnaptysBio currently carries a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks in the biotech sector are Athersys, Inc. ATHX, Kaleido Biosciences, Inc. KLDO and Vertex Pharmaceuticals Incorporated VRTX, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Athersys’ earnings estimates have been revised 21.7% upward for 2022 over the past 60 days.

Earnings of Athersys have surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.

Kaleido Biosciences’ loss per share estimates have narrowed 23% for 2022 over the past 60 days.

Earnings of Kaleido Biosciences have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

Vertex’s earnings estimates have been revised 8.4% upward for 2022 over the past 60 days. The VRTX stock has gained 10.1% year to date.

Vertex’s earnings have surpassed estimates in each of the trailing four quarters.


Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
 
Athersys, Inc. (ATHX): Free Stock Analysis Report
 
AnaptysBio, Inc. (ANAB): Free Stock Analysis Report
 
Kaleido Biosciences, Inc. (KLDO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue